Home / Reports


Medicare data shows savings to be made with generics use

Despite generics accounting for far more claims in the US Medicare system than brand-name drugs, the total costs for each drug still came in much lower than costlier but much less used brand-name drugs.

Asian generics makers to focus on market expansion

According to a report by researchers at Frost & Sullivan (F&S) the Asian generics market will grow at a compound annual growth rate (CAGR) of 17–18% between 2014 and 2018 [1].

The cost of specialty pharmaceuticals

Specialty pharmaceuticals, which include difficult-to-manufacture small-molecule chemical drugs and biologicals, account for approximately 25% of total prescription costs, with expenditures on specialty prescriptions expected to quadruple by 2020 [1]. In fact, the absence of competition upon patent expiration has enabled the cost of biological drugs to increase seemingly without a ceiling.

Pharmacist survey highlights increasing generics costs

A survey of pharmacists has once again highlighted the increasing cost of generics in the US.

European countries should collaborate to reduce drug prices

According to a study published by the World Health Organization (WHO) on 26 March 2015 transparency and cooperation help to reduce high prices for new medicines.

Physicians’ views on biosimilars labelling

On 23 March 2015, the Alliance for Safe Biologic Medicines (ASBM), which represents patients and physicians, as well as originator biological and biosimilars companies in the US, released results of a survey, which showed that physicians ‘support transparent, clear labels with data that enables prescribers to learn about and evaluate the medicines available to their patients’ [1].

US biosimilars approvals expected to increase despite challenges

Biosimilar approvals in the US are expected to increase during the next five years, despite safety and regulatory challenges, according to a study from the Boston-based Tufts Center for the Study of Drug Development (CSDD).

Biosimilars will only be developed for blockbuster biologicals

A new report, published on 24 February 2015, by pharmacy benefits management (PBM) company Prime Therapeutics, suggests that only blockbuster biologicals in the US will be subject to biosimilar competition in the future.

Brazil looks to follow-on biological products to contain costs

Brazil’s Government is looking at measures to control the rising cost of healthcare. With increasing demand for life-saving biologicals the government is considering follow-on biological products as a more cost-effective option [1].

Generics gaining ground in French pharmaceutical market

The French pharmaceutical market is forecast to grow by a miniscule amount in the coming years due to the growing influence of generics in the country.